Unknown PHASE2 INTERVENTIONAL 3-arm NCT02812641

Neoadjuvant CCRT With/Without Bevacizumab for Locally Advanced ESCC

A Randomized Trial of Adding Bevacizumab to Neoadjuvant Platinum-Fluorouracil Concurrent Chemoradiation in Locally Advanced Esophageal Squamous Cell Carcinoma

Sponsor: National Taiwan University Hospital

Conditions Stage III Esophageal Squamous Cell Carcinoma

Interventions BPF-CCRT (randomized) BPF-CCRT (run-in) PF-CCRT (randomized)

Updated 7 times since 2017 Last updated: Mar 7, 2019 Started: Jun 30, 2016 Primary completion: Dec 31, 2019 Completion: Dec 31, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Stage III Esophageal Squamous Cell Carcinoma and is currently ongoing. National Taiwan University Hospital leads this study, which shows 7 recorded versions since 2016 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Mar 2022 — Jul 2024 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status
Jan 2021 — Mar 2022 [monthly]

Recruiting PHASE2
Apr 2019 — Jan 2021 [monthly]

Recruiting PHASE2

▶ Show 2 earlier versions

Jun 2018 — Apr 2019 [monthly]

Recruiting PHASE2
Jan 2017 — Jun 2018 [monthly]

Recruiting PHASE2

First recorded

Jun 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Taiwan University Hospital

Data source: National Taiwan University Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Taipei, Taiwan